| pubmed-article:10738230 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10738230 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:10738230 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:10738230 | lifeskim:mentions | umls-concept:C0021756 | lld:lifeskim |
| pubmed-article:10738230 | lifeskim:mentions | umls-concept:C0278883 | lld:lifeskim |
| pubmed-article:10738230 | lifeskim:mentions | umls-concept:C0205329 | lld:lifeskim |
| pubmed-article:10738230 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:10738230 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:10738230 | pubmed:dateCreated | 2000-4-27 | lld:pubmed |
| pubmed-article:10738230 | pubmed:abstractText | The authors tested a biotherapy regimen involving recombinant interferon-alpha-2a (rIFN-alpha-2a) and recombinant human interleukin-2 (rhIL-2), given in a "decrescendo" schedule over 5 days, for its activity and toxicity in 21 patients who previously had received chemotherapy for advanced melanoma. | lld:pubmed |
| pubmed-article:10738230 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10738230 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10738230 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:10738230 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10738230 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10738230 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10738230 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10738230 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10738230 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10738230 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:10738230 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:10738230 | pubmed:author | pubmed-author:SmithT MTM | lld:pubmed |
| pubmed-article:10738230 | pubmed:author | pubmed-author:LeghaS SSS | lld:pubmed |
| pubmed-article:10738230 | pubmed:author | pubmed-author:BenjaminR SRS | lld:pubmed |
| pubmed-article:10738230 | pubmed:author | pubmed-author:BedikianA YAY | lld:pubmed |
| pubmed-article:10738230 | pubmed:author | pubmed-author:BuzaidA CAC | lld:pubmed |
| pubmed-article:10738230 | pubmed:author | pubmed-author:EtonOO | lld:pubmed |
| pubmed-article:10738230 | pubmed:author | pubmed-author:PapadopoulosN... | lld:pubmed |
| pubmed-article:10738230 | pubmed:author | pubmed-author:EllerhorstJ... | lld:pubmed |
| pubmed-article:10738230 | pubmed:author | pubmed-author:HibbertsJ LJL | lld:pubmed |
| pubmed-article:10738230 | pubmed:copyrightInfo | Copyright 2000 American Cancer Society. | lld:pubmed |
| pubmed-article:10738230 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10738230 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:10738230 | pubmed:volume | 88 | lld:pubmed |
| pubmed-article:10738230 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10738230 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10738230 | pubmed:pagination | 1703-9 | lld:pubmed |
| pubmed-article:10738230 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:10738230 | pubmed:meshHeading | pubmed-meshheading:10738230... | lld:pubmed |
| pubmed-article:10738230 | pubmed:meshHeading | pubmed-meshheading:10738230... | lld:pubmed |
| pubmed-article:10738230 | pubmed:meshHeading | pubmed-meshheading:10738230... | lld:pubmed |
| pubmed-article:10738230 | pubmed:meshHeading | pubmed-meshheading:10738230... | lld:pubmed |
| pubmed-article:10738230 | pubmed:meshHeading | pubmed-meshheading:10738230... | lld:pubmed |
| pubmed-article:10738230 | pubmed:meshHeading | pubmed-meshheading:10738230... | lld:pubmed |
| pubmed-article:10738230 | pubmed:meshHeading | pubmed-meshheading:10738230... | lld:pubmed |
| pubmed-article:10738230 | pubmed:meshHeading | pubmed-meshheading:10738230... | lld:pubmed |
| pubmed-article:10738230 | pubmed:meshHeading | pubmed-meshheading:10738230... | lld:pubmed |
| pubmed-article:10738230 | pubmed:meshHeading | pubmed-meshheading:10738230... | lld:pubmed |
| pubmed-article:10738230 | pubmed:meshHeading | pubmed-meshheading:10738230... | lld:pubmed |
| pubmed-article:10738230 | pubmed:meshHeading | pubmed-meshheading:10738230... | lld:pubmed |
| pubmed-article:10738230 | pubmed:meshHeading | pubmed-meshheading:10738230... | lld:pubmed |
| pubmed-article:10738230 | pubmed:meshHeading | pubmed-meshheading:10738230... | lld:pubmed |
| pubmed-article:10738230 | pubmed:meshHeading | pubmed-meshheading:10738230... | lld:pubmed |
| pubmed-article:10738230 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10738230 | pubmed:articleTitle | A phase II study of "decrescendo" interleukin-2 plus interferon-alpha-2a in patients with progressive metastatic melanoma after chemotherapy. | lld:pubmed |
| pubmed-article:10738230 | pubmed:affiliation | Department of Melanoma/Sarcoma, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. | lld:pubmed |
| pubmed-article:10738230 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10738230 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:10738230 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:10738230 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10738230 | lld:pubmed |
